Published in Proc Natl Acad Sci U S A on February 10, 2005
Molecular interplay between mammalian target of rapamycin (mTOR), amyloid-beta, and Tau: effects on cognitive impairments. J Biol Chem (2010) 3.16
Amyloidogenic light chains induce cardiomyocyte contractile dysfunction and apoptosis via a non-canonical p38alpha MAPK pathway. Proc Natl Acad Sci U S A (2010) 2.41
Functional genomic screen and network analysis reveal novel modifiers of tauopathy dissociated from tau phosphorylation. Hum Mol Genet (2011) 1.72
A dynamic relationship between intracellular and extracellular pools of Abeta. Am J Pathol (2006) 1.66
Inducing autophagy by rapamycin before, but not after, the formation of plaques and tangles ameliorates cognitive deficits. PLoS One (2011) 1.62
Abeta inhibits the proteasome and enhances amyloid and tau accumulation. Neurobiol Aging (2007) 1.58
The significance of the cholinergic system in the brain during aging and in Alzheimer's disease. J Neural Transm (Vienna) (2006) 1.50
Methylene blue reduces aβ levels and rescues early cognitive deficit by increasing proteasome activity. Brain Pathol (2011) 1.46
Detailed immunohistochemical characterization of temporal and spatial progression of Alzheimer's disease-related pathologies in male triple-transgenic mice. BMC Neurosci (2008) 1.44
The role of G protein-coupled receptors in the pathology of Alzheimer's disease. Nat Rev Neurosci (2011) 1.30
Role of vascular risk factors and vascular dysfunction in Alzheimer's disease. Mt Sinai J Med (2010) 1.28
Lithium reduces tau phosphorylation but not A beta or working memory deficits in a transgenic model with both plaques and tangles. Am J Pathol (2007) 1.21
Cholinergic treatments with emphasis on m1 muscarinic agonists as potential disease-modifying agents for Alzheimer's disease. Neurotherapeutics (2008) 1.19
Memantine improves cognition and reduces Alzheimer's-like neuropathology in transgenic mice. Am J Pathol (2009) 1.19
Smoking and increased Alzheimer's disease risk: a review of potential mechanisms. Alzheimers Dement (2014) 1.15
Natural products as a source of Alzheimer's drug leads. Nat Prod Rep (2010) 1.13
Impaired attention in the 3xTgAD mouse model of Alzheimer's disease: rescue by donepezil (Aricept). J Neurosci (2011) 1.11
Children of persons with Alzheimer disease: what does the future hold? Alzheimer Dis Assoc Disord (2008) 0.97
Genetically altering Abeta distribution from the brain to the vasculature ameliorates tau pathology. Brain Pathol (2008) 0.96
β-arrestin1 regulates γ-secretase complex assembly and modulates amyloid-β pathology. Cell Res (2012) 0.95
Cigarette smoking accelerated brain aging and induced pre-Alzheimer-like neuropathology in rats. PLoS One (2012) 0.93
Formulation of a medical food cocktail for Alzheimer's disease: beneficial effects on cognition and neuropathology in a mouse model of the disease. PLoS One (2010) 0.93
Increased risk of dementia in patients exposed to nitrogen dioxide and carbon monoxide: a population-based retrospective cohort study. PLoS One (2014) 0.91
Smoking exacerbates amyloid pathology in a mouse model of Alzheimer's disease. Nat Commun (2013) 0.90
Amyloid beta and the longest-lived rodent: the naked mole-rat as a model for natural protection from Alzheimer's disease. Neurobiol Aging (2013) 0.89
Increased hippocampal excitability in the 3xTgAD mouse model for Alzheimer's disease in vivo. PLoS One (2014) 0.89
Increased risk of dementia in patients with osteoporosis: a population-based retrospective cohort analysis. Age (Dordr) (2013) 0.88
Nicotinic receptors containing the alpha7 subunit: a model for rational drug design. Curr Med Chem (2008) 0.88
Cholinergic and glutamatergic alterations beginning at the early stages of Alzheimer disease: participation of the phospholipase A2 enzyme. Psychopharmacology (Berl) (2008) 0.86
Profile for amyloid-beta and tau expression in primary cortical cultures from 3xTg-AD mice. Cell Mol Neurobiol (2009) 0.86
Oxidative damage and amyloid-β metabolism in brain regions of the longest-lived rodents. J Neurosci Res (2013) 0.86
Gene-environment interaction research and transgenic mouse models of Alzheimer's disease. Int J Alzheimers Dis (2010) 0.85
Autoimmune manifestations in the 3xTg-AD model of Alzheimer's disease. J Alzheimers Dis (2014) 0.83
Dopamine release in prefrontal cortex in response to beta-amyloid activation of alpha7 * nicotinic receptors. Brain Res (2007) 0.83
Neuronal nicotinic receptors as novel targets for inflammation and neuroprotection: mechanistic considerations and clinical relevance. Acta Pharmacol Sin (2009) 0.83
Brain imaging of nicotinic receptors in Alzheimer's disease. Int J Alzheimers Dis (2010) 0.82
Anti-inflammatory and immune therapy for Alzheimer's disease: current status and future directions. Curr Neuropharmacol (2007) 0.82
Amyloid beta: multiple mechanisms of toxicity and only some protective effects? Oxid Med Cell Longev (2014) 0.81
Genetic knockdown of brain-derived neurotrophic factor in 3xTg-AD mice does not alter Aβ or tau pathology. PLoS One (2012) 0.81
Cholinesterase inhibitors may increase phosphorylated tau in Alzheimer's disease. J Neurol (2009) 0.81
Functional alpha7 nicotinic receptors are expressed on immature granule cells of the postnatal dentate gyrus. Brain Res (2014) 0.81
Basal Forebrain Cholinergic Circuits and Signaling in Cognition and Cognitive Decline. Neuron (2016) 0.80
Cholinergic Mechanisms in the Cerebral Cortex: Beyond Synaptic Transmission. Neuroscientist (2015) 0.78
Nicotinic Receptors: Role in Addiction and Other Disorders of the Brain. Subst Abuse (2008) 0.76
Smoking and Alzheimer's disease among Mongolian and Han Chinese aged 55 years and over living in the Inner Mongolia farming area of China. Neural Regen Res (2012) 0.75
Nicotine promotes survival of cells expressing amyloid precursor protein and presenilin: implication for Alzheimer's disease. Neurosci Lett (2013) 0.75
Cholinergic System and Post-translational Modifications: An Insight on the Role in Alzheimer's Disease. Curr Neuropharmacol (2017) 0.75
Alpha7 nicotinic acetylcholine receptor is required for amyloid pathology in brain endothelial cells induced by Glycoprotein 120, methamphetamine and nicotine. Sci Rep (2017) 0.75
Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron (2003) 14.03
Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet (1976) 6.09
Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron (2004) 5.52
Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer's disease. Neurobiol Aging (2003) 3.83
A subtype of nicotinic cholinergic receptor in rat brain is composed of alpha 4 and beta 2 subunits and is up-regulated by chronic nicotine treatment. Mol Pharmacol (1992) 3.20
beta-Amyloid(1-42) binds to alpha7 nicotinic acetylcholine receptor with high affinity. Implications for Alzheimer's disease pathology. J Biol Chem (2000) 2.96
beta-amyloid fibrils induce tau phosphorylation and loss of microtubule binding. Neuron (1995) 2.56
Tau protein pathology in neurodegenerative diseases. Trends Neurosci (1998) 2.37
Beta-amyloid activates the mitogen-activated protein kinase cascade via hippocampal alpha7 nicotinic acetylcholine receptors: In vitro and in vivo mechanisms related to Alzheimer's disease. J Neurosci (2001) 2.15
The influence of smoking on the risk of Alzheimer's disease. Neurology (1999) 2.14
Evidence that neurones accumulating amyloid can undergo lysis to form amyloid plaques in Alzheimer's disease. Histopathology (2001) 2.07
The Alzheimer's A beta peptide induces neurodegeneration and apoptotic cell death in transgenic mice. Nat Genet (1995) 2.03
Tau protein kinase I is essential for amyloid beta-protein-induced neurotoxicity. Proc Natl Acad Sci U S A (1993) 1.92
Measuring nicotinic receptors with characteristics of alpha4beta2, alpha3beta2 and alpha3beta4 subtypes in rat tissues by autoradiography. J Neurochem (2002) 1.75
Intracellular accumulation of beta-amyloid(1-42) in neurons is facilitated by the alpha 7 nicotinic acetylcholine receptor in Alzheimer's disease. Neuroscience (2002) 1.73
p38 kinase is activated in the Alzheimer's disease brain. J Neurochem (1999) 1.50
beta -Amyloid peptide activates alpha 7 nicotinic acetylcholine receptors expressed in Xenopus oocytes. J Biol Chem (2002) 1.32
Smoking and Alzheimer's disease: a review of the epidemiological evidence. Neuroepidemiology (1994) 1.31
Inhibition of tau phosphorylating protein kinase cdk5 prevents beta-amyloid-induced neuronal death. FEBS Lett (1999) 1.27
Nicotinic acetylcholine binding sites in Alzheimer's disease. Brain Res (1986) 1.26
Acetylcholine, aging, and Alzheimer's disease. Pharmacol Biochem Behav (1997) 1.15
Nicotinic and muscarinic subtypes in the human brain: changes with aging and dementia. J Neurosci Res (1992) 1.07
Reduced number of [3H]nicotine and [3H]acetylcholine binding sites in the frontal cortex of Alzheimer brains. Neurosci Lett (1986) 1.03
Quantitative assessment of nicotinic acetylcholine receptor proteins in the cerebral cortex of Alzheimer patients. Brain Res Mol Brain Res (2000) 1.02
Amyloid beta-peptide: the inside story. Curr Alzheimer Res (2004) 0.99
Chronic nicotine treatment reduces beta-amyloidosis in the brain of a mouse model of Alzheimer's disease (APPsw). J Neurochem (2002) 0.99
The nicotinic acetylcholine receptor, smoking, and Alzheimer's disease. J Alzheimers Dis (2002) 0.98
Alpha 7 nicotinic acetylcholine receptors mediate beta-amyloid peptide-induced tau protein phosphorylation. J Biol Chem (2003) 0.97
Acetylcholinesterase inhibition in Alzheimer's Disease. Curr Pharm Des (2004) 0.95
Human nicotinic receptors--their role in aging and dementia. Neurochem Int (1994) 0.95
Cellular expression of alpha7 nicotinic acetylcholine receptor protein in the temporal cortex in Alzheimer's and Parkinson's disease--a stereological approach. Neurobiol Dis (2000) 0.92
Increased levels of tau protein in SH-SY5Y cells after treatment with cholinesterase inhibitors and nicotinic agonists. J Neurochem (2000) 0.91
Nicotine reduces A beta in the brain and cerebral vessels of APPsw mice. Eur J Neurosci (2004) 0.91
Expression of nicotinic acetylcholine receptor subunits in the cerebral cortex in Alzheimer's disease: histotopographical correlation with amyloid plaques and hyperphosphorylated-tau protein. Eur J Neurosci (1999) 0.90
Nicotinic acetylcholine receptor subtypes in human frontal cortex: changes in Alzheimer's disease. J Neurosci Res (1990) 0.87
The interrelationship between selective tau phosphorylation and microtubule association. Brain Res (1998) 0.86
Does smoking protect from Alzheimer's disease? Alzheimer-type changes in 301 unselected brains from patients with known smoking history. Acta Neuropathol (1997) 0.86
p38 mitogen activated protein kinase as a therapeutic target for Alzheimer's disease. J Mol Neurosci (2002) 0.85
Expression of nicotinic acetylcholine receptors in Alzheimer's disease: postmortem investigations and experimental approaches. Behav Brain Res (2000) 0.84
Calcium regulation of agonist binding to alpha7-type nicotinic acetylcholine receptors in adult and fetal rat hippocampus. J Neurochem (1998) 0.82
The critical role of cholinergic basal forebrain neurons in morphological change and memory encoding: a hypothesis. Neurobiol Learn Mem (1996) 0.82
Nicotinic acetylcholine receptors in Alzheimer's disease. J Alzheimers Dis (1999) 0.79
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Triple-transgenic model of Alzheimer's disease with plaques and tangles: intracellular Abeta and synaptic dysfunction. Neuron (2003) 14.03
Alzheimer's disease. N Engl J Med (2010) 13.13
Using internet searches for influenza surveillance. Clin Infect Dis (2008) 11.11
Intraneuronal Abeta causes the onset of early Alzheimer's disease-related cognitive deficits in transgenic mice. Neuron (2005) 6.20
Intracellular amyloid-beta in Alzheimer's disease. Nat Rev Neurosci (2007) 5.72
Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron (2004) 5.52
Prokineticin 2 transmits the behavioural circadian rhythm of the suprachiasmatic nucleus. Nature (2002) 4.67
Amyloid deposition precedes tangle formation in a triple transgenic model of Alzheimer's disease. Neurobiol Aging (2003) 3.83
Lipopolysaccharide-induced inflammation exacerbates tau pathology by a cyclin-dependent kinase 5-mediated pathway in a transgenic model of Alzheimer's disease. J Neurosci (2005) 3.18
The dynamic effects of nicotine on the developing brain. Pharmacol Ther (2009) 3.01
Neural stem cells improve cognition via BDNF in a transgenic model of Alzheimer disease. Proc Natl Acad Sci U S A (2009) 2.96
Caspase-cleavage of tau is an early event in Alzheimer disease tangle pathology. J Clin Invest (2004) 2.80
Microglial Cx3cr1 knockout prevents neuron loss in a mouse model of Alzheimer's disease. Nat Neurosci (2010) 2.79
Temporal profile of amyloid-beta (Abeta) oligomerization in an in vivo model of Alzheimer disease. A link between Abeta and tau pathology. J Biol Chem (2005) 2.56
Glucocorticoids increase amyloid-beta and tau pathology in a mouse model of Alzheimer's disease. J Neurosci (2006) 2.45
Reduction of soluble Abeta and tau, but not soluble Abeta alone, ameliorates cognitive decline in transgenic mice with plaques and tangles. J Biol Chem (2006) 2.33
Enhanced ryanodine receptor recruitment contributes to Ca2+ disruptions in young, adult, and aged Alzheimer's disease mice. J Neurosci (2006) 2.32
IKK phosphorylates Huntingtin and targets it for degradation by the proteasome and lysosome. J Cell Biol (2009) 2.16
Synergistic Interactions between Abeta, tau, and alpha-synuclein: acceleration of neuropathology and cognitive decline. J Neurosci (2010) 2.12
Dependence of olfactory bulb neurogenesis on prokineticin 2 signaling. Science (2005) 2.08
M1 receptors play a central role in modulating AD-like pathology in transgenic mice. Neuron (2006) 2.07
Progesterone and estrogen regulate Alzheimer-like neuropathology in female 3xTg-AD mice. J Neurosci (2007) 2.00
A physiologic signaling role for the gamma -secretase-derived intracellular fragment of APP. Proc Natl Acad Sci U S A (2002) 1.97
Acetaldehyde enhances acquisition of nicotine self-administration in adolescent rats. Neuropsychopharmacology (2005) 1.96
Dysregulated IP3 signaling in cortical neurons of knock-in mice expressing an Alzheimer's-linked mutation in presenilin1 results in exaggerated Ca2+ signals and altered membrane excitability. J Neurosci (2004) 1.92
Nicotinamide restores cognition in Alzheimer's disease transgenic mice via a mechanism involving sirtuin inhibition and selective reduction of Thr231-phosphotau. J Neurosci (2008) 1.88
SERCA pump activity is physiologically regulated by presenilin and regulates amyloid beta production. J Cell Biol (2008) 1.84
Linking calcium to Abeta and Alzheimer's disease. Neuron (2008) 1.82
Age-dependent effects of nicotine on locomotor activity and conditioned place preference in rats. Psychopharmacology (Berl) (2004) 1.81
Nicotine and brain development. Birth Defects Res C Embryo Today (2008) 1.80
Inflammation induces tau pathology in inclusion body myositis model via glycogen synthase kinase-3beta. Ann Neurol (2008) 1.71
Expression of neuronal nicotinic acetylcholine receptor subunit mRNAs within midbrain dopamine neurons. J Comp Neurol (2002) 1.68
Age- and region-dependent alterations in Abeta-degrading enzymes: implications for Abeta-induced disorders. Neurobiol Aging (2005) 1.68
A dynamic relationship between intracellular and extracellular pools of Abeta. Am J Pathol (2006) 1.66
Treatment with a C5aR antagonist decreases pathology and enhances behavioral performance in murine models of Alzheimer's disease. J Immunol (2009) 1.66
Early correlation of microglial activation with enhanced tumor necrosis factor-alpha and monocyte chemoattractant protein-1 expression specifically within the entorhinal cortex of triple transgenic Alzheimer's disease mice. J Neuroinflammation (2005) 1.64
Impaired adult neurogenesis in the dentate gyrus of a triple transgenic mouse model of Alzheimer's disease. PLoS One (2008) 1.62
Inhibition of soluble TNF signaling in a mouse model of Alzheimer's disease prevents pre-plaque amyloid-associated neuropathology. Neurobiol Dis (2009) 1.60
Calpain inhibitor A-705253 mitigates Alzheimer's disease-like pathology and cognitive decline in aged 3xTgAD mice. Am J Pathol (2012) 1.60
Abeta inhibits the proteasome and enhances amyloid and tau accumulation. Neurobiol Aging (2007) 1.58
Ibuprofen reduces Abeta, hyperphosphorylated tau and memory deficits in Alzheimer mice. Brain Res (2008) 1.56
Chronic neuron-specific tumor necrosis factor-alpha expression enhances the local inflammatory environment ultimately leading to neuronal death in 3xTg-AD mice. Am J Pathol (2008) 1.55
Smoking to self-medicate attentional and emotional dysfunctions. Nicotine Tob Res (2007) 1.54
Enhanced caffeine-induced Ca2+ release in the 3xTg-AD mouse model of Alzheimer's disease. J Neurochem (2005) 1.52
Calcium dysregulation in Alzheimer's disease: recent advances gained from genetically modified animals. Cell Calcium (2005) 1.52
Females exhibit more extensive amyloid, but not tau, pathology in an Alzheimer transgenic model. Brain Res (2008) 1.51
Blocking Abeta42 accumulation delays the onset and progression of tau pathology via the C terminus of heat shock protein70-interacting protein: a mechanistic link between Abeta and tau pathology. J Neurosci (2008) 1.49
Dietary docosahexaenoic acid and docosapentaenoic acid ameliorate amyloid-beta and tau pathology via a mechanism involving presenilin 1 levels. J Neurosci (2007) 1.47
Controlled cortical impact traumatic brain injury in 3xTg-AD mice causes acute intra-axonal amyloid-β accumulation and independently accelerates the development of tau abnormalities. J Neurosci (2011) 1.47
Methylene blue reduces aβ levels and rescues early cognitive deficit by increasing proteasome activity. Brain Pathol (2011) 1.46
Neural stem cells improve memory in an inducible mouse model of neuronal loss. J Neurosci (2007) 1.46
Lifelong rapamycin administration ameliorates age-dependent cognitive deficits by reducing IL-1β and enhancing NMDA signaling. Aging Cell (2012) 1.43
Relevance of transgenic mouse models to human Alzheimer disease. J Biol Chem (2008) 1.36
Blocking IL-1 signaling rescues cognition, attenuates tau pathology, and restores neuronal β-catenin pathway function in an Alzheimer's disease model. J Immunol (2011) 1.36
Expression of prokineticins and their receptors in the adult mouse brain. J Comp Neurol (2006) 1.34
Sustained interleukin-1β overexpression exacerbates tau pathology despite reduced amyloid burden in an Alzheimer's mouse model. J Neurosci (2013) 1.32
Age-dependent sexual dimorphism in cognition and stress response in the 3xTg-AD mice. Neurobiol Dis (2007) 1.30
Enhanced neuronal excitability in the absence of neurodegeneration induces cerebellar ataxia. J Clin Invest (2004) 1.29
Mifepristone alters amyloid precursor protein processing to preclude amyloid beta and also reduces tau pathology. Biol Psychiatry (2013) 1.28
Intraneuronal beta-amyloid accumulation in the amygdala enhances fear and anxiety in Alzheimer's disease transgenic mice. Biol Psychiatry (2009) 1.25
Intranasal NAP administration reduces accumulation of amyloid peptide and tau hyperphosphorylation in a transgenic mouse model of Alzheimer's disease at early pathological stage. J Mol Neurosci (2007) 1.24
ACAT1 gene ablation increases 24(S)-hydroxycholesterol content in the brain and ameliorates amyloid pathology in mice with AD. Proc Natl Acad Sci U S A (2010) 1.23
AT-1001: a high affinity and selective α3β4 nicotinic acetylcholine receptor antagonist blocks nicotine self-administration in rats. Neuropsychopharmacology (2012) 1.22
Genetically augmenting tau levels does not modulate the onset or progression of Abeta pathology in transgenic mice. J Neurochem (2007) 1.22
Learning decreases A beta*56 and tau pathology and ameliorates behavioral decline in 3xTg-AD mice. J Neurosci (2007) 1.22
Low dose nicotine treatment during early adolescence increases subsequent cocaine reward. Neurotoxicol Teratol (2006) 1.22
Androgens regulate the development of neuropathology in a triple transgenic mouse model of Alzheimer's disease. J Neurosci (2006) 1.21
Development of the alpha7 nicotinic cholinergic receptor in rat hippocampal formation. Brain Res Dev Brain Res (2002) 1.21
Lithium reduces tau phosphorylation but not A beta or working memory deficits in a transgenic model with both plaques and tangles. Am J Pathol (2007) 1.21
Memantine improves cognition and reduces Alzheimer's-like neuropathology in transgenic mice. Am J Pathol (2009) 1.19
Animal models of Alzheimer disease. Cold Spring Harb Perspect Med (2012) 1.18
Presenilin is necessary for efficient proteolysis through the autophagy-lysosome system in a γ-secretase-independent manner. J Neurosci (2011) 1.18